Table 2

Inclusion and exclusion criteria and search strategy* for studies investigating the use of noradrenergic treatments in neurodegenerative conditions

Inclusion criteriaExclusion criteria
Study published between 1980 and 22 December 2021Study published prior to 1980
Peer reviewedEditorials, review articles, letters, or case reports
Prospective trialConference abstracts
Placebo controlledNo placebo group
n>1Single dose studies
Any ageNot in English
Study includes predominantly patients with the included diagnoses (or subgroup analysis including patients with the included diagnoses)Poorly defined patient cohort for example, ‘dementia’
Study reports either a change in recognised score of cognition and/or psychological/psychiatric symptoms/behaviourData not accessible, including after request from authors if necessary
For studies reporting duplicated data, the most recent or most comprehensive publication to be indexedDuplicate data
English language
Study of drug with principally noradrenergic action
  • *Search was done using the following terms ($is used as a truncation command): ((Alzheimer$ or Parkinson$ or “Lewy bod$” or “Frontotemporal d$” or “progressive supranuclear palsy” or “mild cognitive impairment”) and (cogniti$ or behav$ or psychiatric or psychological or memory or attention) and (noradren$ or norepineph$ or epineph$ or adrenergic or “vesicular monoamine transporter inhibitor” or catechol-O-methyltransferase or “Phenylalanine hydroxylase inhibitor” or “Tyrosine hydroxylase inhibitor” or "Aromatic L-amino acid decarboxylase inhibitor” or “Dopamine-beta-hydroxylase inhibitor” or “Phenylethanolamine N-methyltransferase” or guanfacine or atomoxetine or methylphenidate or clonidine or yohimbine or prazosin or mirtazapine) and (trial or control$ or experimental or placebo).mp.)